| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
N/A |
| Shares
Out: |
61,150,000 |
| Market
Cap: |
6.68(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$113.49 - $145.93 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious diseases with limited or no options. Co.'s primary marketed products are: Xyrem® (sodium oxybate) oral solution, for the treatment of both cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; and Sunosi® (solriamfetol), to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
12,000 |
12,000 |
12,000 |
12,000 |
| Total Buy Value |
$1,435,800 |
$1,435,800 |
$1,435,800 |
$1,435,800 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
3,704 |
4,538 |
27,327 |
202,315 |
| Total Sell Value |
$438,449 |
$537,921 |
$3,641,323 |
$29,586,917 |
| Total People Sold |
1 |
3 |
13 |
19 |
| Total Sell Transactions |
2 |
4 |
21 |
79 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Patil Neena M |
EVP & Chief Legal Officer |
• – – |
2023-03-05 |
4 |
D |
$142.78 |
$274,566 |
D/D |
(1,923) |
34,339 |
|
- |
|
| Sablich Kim |
EVP, GM of U.S., Commercial Ma |
• – – |
2023-03-05 |
4 |
D |
$142.78 |
$229,876 |
D/D |
(1,610) |
33,573 |
|
- |
|
| Pearce Samantha |
SVP, Head of Europe & Internat |
• – – |
2023-03-05 |
4 |
D |
$142.78 |
$288,416 |
D/D |
(2,020) |
13,159 |
|
- |
|
| Gala Renee D |
EVP & Chief Financial Officer |
• – – |
2023-03-05 |
4 |
D |
$142.78 |
$222,308 |
D/D |
(1,557) |
43,785 |
|
- |
|
| Iannone Robert |
EVP, Global Head of Research a |
• – – |
2023-03-05 |
4 |
D |
$142.78 |
$324,682 |
D/D |
(2,274) |
46,489 |
|
- |
|
| Swisher Daniel N Jr |
President and COO |
• – – |
2023-03-05 |
4 |
D |
$142.78 |
$774,724 |
D/D |
(5,426) |
55,014 |
|
- |
|
| Mulligan Seamus |
Director |
– • – |
2023-03-04 |
4 |
OE |
$59.13 |
$266,085 |
D/D |
4,500 |
1,164,800 |
|
- |
|
| Carr Patricia |
SVP, Chief Accounting Officer |
• – – |
2023-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,523 |
8,457 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2023-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
42,388 |
409,466 |
|
- |
|
| Patil Neena M |
EVP & Chief Legal Officer |
• – – |
2023-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
9,419 |
36,262 |
|
- |
|
| Larkin Finbar |
SVP, Technical Operations |
• – – |
2023-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
4,373 |
23,854 |
|
- |
|
| Sablich Kim |
EVP, GM of U.S., Commercial Ma |
• – – |
2023-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
10,429 |
35,183 |
|
- |
|
| Pearce Samantha |
SVP, Head of Europe & Internat |
• – – |
2023-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
3,870 |
15,179 |
|
- |
|
| Gala Renee D |
EVP & Chief Financial Officer |
• – – |
2023-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
12,784 |
45,342 |
|
- |
|
| Iannone Robert |
EVP, Global Head of Research a |
• – – |
2023-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
12,447 |
48,763 |
|
- |
|
| Swisher Daniel N Jr |
President and COO |
• – – |
2023-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
13,456 |
60,440 |
|
- |
|
| Pearce Samantha |
SVP, Head of Europe & Internat |
• – – |
2023-02-02 |
4 |
AS |
$157.26 |
$83,505 |
D/D |
(531) |
11,309 |
|
- |
|
| Pearce Samantha |
SVP, Head of Europe & Internat |
• – – |
2023-02-02 |
4 |
OE |
$109.45 |
$58,118 |
D/D |
531 |
11,840 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2023-02-01 |
4 |
AS |
$155.79 |
$155,790 |
D/D |
(1,000) |
367,078 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2023-01-03 |
4 |
AS |
$159.59 |
$479,590 |
D/D |
(3,000) |
368,078 |
|
- |
|
| Pearce Samantha |
SVP, Head of Europe & Internat |
• – – |
2023-01-03 |
4 |
AS |
$159.59 |
$84,742 |
D/D |
(531) |
11,309 |
|
- |
|
| Pearce Samantha |
SVP, Head of Europe & Internat |
• – – |
2023-01-03 |
4 |
OE |
$109.45 |
$58,118 |
D/D |
531 |
11,840 |
|
- |
|
| Gala Renee D |
EVP & Chief Financial Officer |
• – – |
2022-12-21 |
4 |
AS |
$160.00 |
$421,600 |
D/D |
(2,635) |
32,558 |
|
- |
|
| Pearce Samantha |
SVP, Head of Europe & Internat |
• – – |
2022-12-13 |
4 |
AS |
$155.45 |
$82,544 |
D/D |
(531) |
11,309 |
|
- |
|
| Pearce Samantha |
SVP, Head of Europe & Internat |
• – – |
2022-12-13 |
4 |
OE |
$109.45 |
$58,118 |
D/D |
531 |
11,840 |
|
- |
|
1249 Records found
|
|
Page 4 of 50 |
|
|
0.37 (0.34%) 
